Tacrolimus and Red blood cell abnormality - a phase IV clinical study of FDA data

Summary:

Red blood cell abnormality is reported as a side effect among people who take Tacrolimus (tacrolimus), especially for people who are male, 60+ old, also take Cyclosporine, and have High blood pressure.

The phase IV clinical study analyzes which people have Red blood cell abnormality when taking Tacrolimus. It is created by eHealthMe based on reports of 115,828 people who have side effects when taking Tacrolimus from the FDA, and is updated regularly.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,160 Tacrolimus users. Check the latest studies of Tacrolimus.

What is Red blood cell abnormality?

Red blood cell abnormality (abnormal red blood cells) is found to be associated with 196 drugs and 332 conditions by eHealthMe. Check the latest studies of Red blood cell abnormality.

On Jul, 15, 2026

115,828 people reported to have side effects when taking Tacrolimus.
Among them, 12 people (0.01%) have Red blood cell abnormality.

Could Tacrolimus cause Red blood cell abnormality?

Among these 12 people:

What is the gender of people who have Red blood cell abnormality when taking Tacrolimus? *

female: 44.44 %
male: 55.56 %

What is the age of people who have Red blood cell abnormality when taking Tacrolimus? *

What are other drugs people take besides Tacrolimus? *

What are other side effects people have besides Red blood cell abnormality? *

Thrombocytopenia (decrease of platelets in blood): 9 people, 75.00%
Thrombotic Microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury): 6 people, 50.00%
Anaemia (lack of blood): 6 people, 50.00%
High Blood Pressure: 4 people, 33.33%
Blood Lactate Dehydrogenase Increased: 4 people, 33.33%
Renal Impairment (severely reduced kidney function): 4 people, 33.33%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 3 people, 25.00%
Haptoglobin Decreased: 3 people, 25.00%
Gastric Haemorrhage (bleeding stomach): 2 people, 16.67%
Pneumonia: 2 people, 16.67%

What are the existing conditions these people have? *

Urination - Excessive Volume: 1 person, 8.33%
Stress And Anxiety: 1 person, 8.33%
Osteoporosis (bones weak and more likely to break): 1 person, 8.33%
Nephrogenic Anaemia (anaemia due to kidney disease): 1 person, 8.33%
Multiple Myeloma (cancer of the plasma cells): 1 person, 8.33%
Kidney Transplant Rejection: 1 person, 8.33%
Interstitial Lung Disease: 1 person, 8.33%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 8.33%
Hypersensitivity: 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Tacrolimus and have Red blood cell abnormality?

- Check whether Red blood cell abnormality is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tacrolimus:

Tacrolimus (116,160 reports)

Browse all side effects of Tacrolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Red blood cell abnormality:

Red blood cell abnormality (196 drugs)

Browse all the conditions that are associated with Red blood cell abnormality:

Red blood cell abnormality (332 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Tacrolimus) and Tacrolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.